[go: up one dir, main page]

JOP20190152A1 - مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة - Google Patents

مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Info

Publication number
JOP20190152A1
JOP20190152A1 JOP/2019/0152A JOP20190152A JOP20190152A1 JO P20190152 A1 JOP20190152 A1 JO P20190152A1 JO P20190152 A JOP20190152 A JO P20190152A JO P20190152 A1 JOP20190152 A1 JO P20190152A1
Authority
JO
Jordan
Prior art keywords
activin
myostatin
receptor antagonists
related conditions
treating obesity
Prior art date
Application number
JOP/2019/0152A
Other languages
English (en)
Inventor
Tania Silvia Garito
Marjorie Zakaria
Ronenn Roubenoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190152A1 publication Critical patent/JOP20190152A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

يتعلق الاختراع الحالي بمضادات ميوستاتين أو آكتيفين أو مضادات مستقبل للاستخدام في تحسين تركيبة الجسم، مثلا، لعلاج البدانة المركزية، السمنة أو حالة زيادة الوزن والأمراض المصاحبة ذات الصلة. يتعلق الاختراع الحالي بمضادات ميوستاتين أو آكتيفين أو مضادات مستقبل لعلاج السكري من النوع II بواسطة تحسين التحكم في سكر الدم، تحديدا بواسطة زيادة حساسية الإنسولين. الشكل 1
JOP/2019/0152A 2016-12-21 2017-06-16 مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة JOP20190152A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662437097P 2016-12-21 2016-12-21

Publications (1)

Publication Number Publication Date
JOP20190152A1 true JOP20190152A1 (ar) 2019-06-20

Family

ID=60972283

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0152A JOP20190152A1 (ar) 2016-12-21 2017-06-16 مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Country Status (15)

Country Link
US (2) US20190345251A1 (ar)
EP (1) EP3558361A1 (ar)
JP (2) JP7280825B2 (ar)
KR (2) KR20190097138A (ar)
CN (2) CN110087684B (ar)
AU (1) AU2017380844B2 (ar)
BR (1) BR112019012661A2 (ar)
CA (1) CA3042965A1 (ar)
CL (1) CL2019001683A1 (ar)
IL (1) IL267471A (ar)
JO (1) JOP20190152A1 (ar)
MX (2) MX2019007581A (ar)
PH (1) PH12019501026A1 (ar)
TW (2) TWI848773B (ar)
WO (1) WO2018116201A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
IL258121B2 (en) 2015-09-15 2024-01-01 Scholar Rock Inc Antipro/latent myostatin antibodies and their uses
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
SI3368069T1 (sl) 2016-06-13 2021-03-31 Scholar Rock, Inc. Uporaba zaviralcev miostatina in kombinirane terapije
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
GB201706857D0 (en) 2017-04-28 2017-06-14 Select Res Ltd Health risk prediction tools
CA3104053A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazole derivatives as malt1 inhibitors
JP7663559B2 (ja) 2019-09-03 2025-04-16 ノバルティス アーゲー Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
US20240124541A1 (en) * 2021-04-12 2024-04-18 University of Florida Research Foundation, Incorprated Compositions and methods for treating obesity
AU2022299185A1 (en) * 2021-06-23 2024-01-25 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
MX2024002467A (es) 2021-08-27 2024-05-20 Versanis Bio Inc Terapias combinadas.
JP2025504453A (ja) * 2022-01-19 2025-02-12 バーサニス バイオ、インコーポレイテッド ＡｃｔＲＩＩ抗体治療
KR20250051760A (ko) 2022-08-26 2025-04-17 버사니스 바이오, 인크. Actrii 항체 고정 단위 용량 치료
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076402A1 (es) 2009-04-27 2011-06-08 Novartis Ag Composiciones y metodos para aumentar el crecimiento muscular
US8178488B2 (en) * 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) * 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
KR20200086378A (ko) * 2009-09-09 2020-07-16 악셀레론 파마 인코포레이티드 ＡｃｔＲＩＩｂ 길항제들와 이의 투약 및 용도
US9365651B2 (en) * 2011-07-01 2016-06-14 Novartis Ag Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
AU2013274347B2 (en) * 2012-06-11 2018-03-08 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
CN106999589A (zh) * 2014-12-08 2017-08-01 诺华股份有限公司 用于治疗肌肉减少症的肌肉生长抑制素或激活素拮抗剂
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
US11357851B2 (en) * 2015-11-11 2022-06-14 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof

Also Published As

Publication number Publication date
KR20240147705A (ko) 2024-10-08
KR20190097138A (ko) 2019-08-20
TWI812606B (zh) 2023-08-21
TW202417043A (zh) 2024-05-01
JP2020511422A (ja) 2020-04-16
EP3558361A1 (en) 2019-10-30
RU2765288C2 (ru) 2022-01-28
BR112019012661A2 (pt) 2020-01-28
US20210363263A1 (en) 2021-11-25
AU2017380844A1 (en) 2019-05-16
WO2018116201A1 (en) 2018-06-28
MX2024001135A (es) 2024-02-27
CL2019001683A1 (es) 2019-09-13
PH12019501026A1 (en) 2019-12-16
RU2019119375A3 (ar) 2021-01-29
IL267471A (en) 2019-08-29
MX2019007581A (es) 2019-09-04
CN110087684B (zh) 2023-12-01
AU2017380844B2 (en) 2024-12-19
TWI848773B (zh) 2024-07-11
JP2023052026A (ja) 2023-04-11
RU2019119375A (ru) 2021-01-22
TW201825120A (zh) 2018-07-16
CN110087684A (zh) 2019-08-02
JP7280825B2 (ja) 2023-05-24
CA3042965A1 (en) 2018-06-28
US20190345251A1 (en) 2019-11-14
CN118105478A (zh) 2024-05-31

Similar Documents

Publication Publication Date Title
MX2024001135A (es) Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
CY1119987T1 (el) Παραγωγα εξενδινης-4 ως διττοι αγωνιστες glp1/γλυκαγονης
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
MX2016004907A (es) Analogos del glucagon.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
IN2014CN04401A (ar)
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX362190B (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
EA201590294A1 (ru) Аналоги глюкагона
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX386595B (es) Métodos para el tratamiento del sobrepeso o la obesidad.
MX2017012864A (es) Analogo acilado del glucagon.
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
NZ739392A (en) Methods for treating hepcidin-mediated disorders
BR112017008045A2 (pt) compostos como inibidores de nik
MX2015015249A (es) Peptidos terapeuticos.
GB2546713A (en) Neuromodulation device
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
MX2017000222A (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.
TR201909078T4 (tr) Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı.